Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)

This study has been withdrawn prior to enrollment.
(Few patients would like to participate ,since CIK cell transfusion was a new treatment and its efficacy was doubted.)
Information provided by (Responsible Party):
Li Zhang, Sun Yat-sen University Identifier:
First received: February 12, 2012
Last updated: December 5, 2013
Last verified: February 2012
No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: December 2020
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)